Unique profile on the progress free survival and overall survival in patients with advanced non-small cell lung cancer in the Qujing area, Southwest China
Yuhui Ma(Xinhui People's Hospital), Yunchao Huang(North China University of Water Resources and Electric Power), Hutao Shi(Kunming Tongren Hospital), Chaojiang Fu(Second People's Hospital of Yunnan Province), Xin Liu(University of Southern California), Li Zhao(Guangxi Medical University), Guangqiang Zhao(Kunming Medical University), Wanlin Chen(Zhejiang Lab), Lianhua Ye(Kunming Medical University), Yujie Lei(Nanjing University of Information Science and Technology), Jingjing Cai(Anhui Institute of Architectural Research and Design), Yongchun Zhou(Kunming Medical University), Guangjian Li(Hohai University)
Cited by 0
Related Papers
Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes
|Cell Metabolism|2020|1.7k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508